Skip to main content

Laronix

Category: AI in Healthcare

Laronix develops AI-powered bionic voice technology and wearable electronic voice prostheses for individuals with voice loss. Laronix was founded in 2018. The company is led by Dr. Farzaneh Ahmadi. Based in Brisbane, Australia. Team size: 10-50. Total funding raised: $3.32M. Latest round: Grant - III. Key investors include Australian Government Industry Growth Program, Google for Startups, MedTech Innovator, Scale Investors, Australian angels.

Founded
2018
Headquarters
Brisbane, Australia
Team size
10-50
Total funding
$3.32M

Value proposition

Restores natural-sounding voice through non-invasive, smart wearable technology, improving quality of life for voice-impaired individuals

Products and solutions

AVA Voice™ (AI-powered electronic voice prosthesis), MIRA Voice™ (Innovative voicing device for all types of voice loss), Bionic Voice™ (Future generation smart, hands-free voicing device)

Unique value

Integration of AI with wearable medical devices for real-time voice synthesis, combined with non-invasive design for patient comfort

Target customer

Laryngectomy patients (individuals who have undergone larynx removal) and others experiencing severe or permanent voice loss

Industries served

Medical Devices, Healthcare AI, Therapeutic Technologies

Technology advantage

Proprietary AI algorithms trained on patient-specific vocal patterns, enabling personalized voice restoration; first-to-market smart wearable voice prosthesis

How they differentiate

Laronix differentiates itself through AI-powered smart wearable technology that learns and mimics a patient's natural voice patterns, offering a more personalized and adaptive solution compared to traditional electronic larynx devices

Main competitors

Atos Medical (Coloplast A/S), InHealth Technologies, Tobii Dynavox, Smartbox, Control Bionics

Key partnerships

Western Sydney University (research collaboration), Australian Government Industry Growth Program (funding), Clinical partners for patient trials, GBMC HealthCare (US partnership)

Notable customers

Laryngectomy patients in clinical trials, Healthcare institutions in Australia and US, GBMC HealthCare partnership

Major milestones

Secured $3.2M Australian government grant in 2025, Completed preclinical trials for MIRA Voice, AVA Voice commercialization launched in Australia (2024), ISO-13485 certification achieved, Partnerships with healthcare providers in Australia and US

Growth metrics

Successful preclinical trials, clinical testing underway, ISO-13485 certified medical device manufacturer, AVA Voice commercially launched in Australia (2024)

Market positioning

Positioned as an innovator in AI-driven voice restoration, targeting laryngectomy patients and broader voice-loss populations with non-invasive, wearable solutions

Geographic focus

Primarily focused on Australia and the Asia-Pacific region, with expansion plans into North America and Europe

Patents and IP

Pending patents related to AI-driven voice synthesis and bionic voice prosthesis design (specifics not disclosed publicly)

About Dr. Farzaneh Ahmadi

Dr. Farzaneh Ahmadi has over 12 years of expertise in industrial R&D and academic research. She successfully delivered R&D projects worth over $2 million and raised over $1 million in academic grants since 2015 for her bionic voice invention. She has guided the technology from inception through successful preclinical trials and was the scientific lead of Bionic Voice research at Western Sydney University.

Official website: